NCT01765868View on ClinicalTrials.gov

A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Healthy Subjects
Interventions
DRUG

Betrixaban

Single Oral dose 80 mg betrixaban and Single IV (15 ml) carbon 14 80 micrograms Betrixaban administered over 15 minutes, 2 hours after the oral dose

Sponsors
All Listed Sponsors
lead

Portola Pharmaceuticals

INDUSTRY